Innova Captab Limited
Innova Captab Limited (INNOVACAP) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
innovacaptab.com(opens the company website in a new tab)Key metrics
Price as of 2026-09-03
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 283 Cr | 302 Cr | 263 Cr | 294 Cr | 318 Cr | 316 Cr | 315 Cr | 352 Cr | 380 Cr | 450 Cr | 448 Cr | 471 Cr |
| Operating expenses (approx.) | 242 Cr | 258 Cr | 225 Cr | 252 Cr | 268 Cr | 270 Cr | 267 Cr | 299 Cr | 329 Cr | 381 Cr | 383 Cr | 398 Cr |
| EBITDA | 40 Cr | 45 Cr | 38 Cr | 42 Cr | 50 Cr | 47 Cr | 48 Cr | 52 Cr | 52 Cr | 69 Cr | 65 Cr | 73 Cr |
| OPM % | 14.3% | 14.7% | 14.5% | 14.3% | 15.6% | 14.7% | 15.2% | 14.8% | 13.6% | 15.4% | 14.5% | 15.5% |
| Other income | 3 Cr | 2 Cr | 6 Cr | 2 Cr | 2 Cr | 4 Cr | 3 Cr | 4 Cr | 4 Cr | 2 Cr | 2 Cr | 2 Cr |
| Interest | 9 Cr | 7 Cr | 0.81 Cr | 0.14 Cr | 0.15 Cr | 0.17 Cr | 2 Cr | 3 Cr | 5 Cr | 4 Cr | 5 Cr | 4 Cr |
| Depreciation | 5 Cr | 5 Cr | 3 Cr | 5 Cr | 5 Cr | 5 Cr | 10 Cr | 11 Cr | 11 Cr | 11 Cr | 11 Cr | 12 Cr |
| Profit before tax | 30 Cr | 35 Cr | 40 Cr | 39 Cr | 47 Cr | 46 Cr | 39 Cr | 43 Cr | 39 Cr | 56 Cr | 51 Cr | 59 Cr |
| Tax % | 24.1% | 28.6% | 27.4% | 25.0% | 25.2% | 25.0% | 24.8% | 27.3% | 24.4% | 24.3% | 24.8% | 25.2% |
| Net profit | 23 Cr | 25 Cr | 29 Cr | 29 Cr | 35 Cr | 34 Cr | 30 Cr | 31 Cr | 30 Cr | 42 Cr | 38 Cr | 44 Cr |
| EPS (₹) | ₹4.77 | ₹4.39 | ₹5.02 | ₹5.15 | ₹6.12 | ₹5.97 | ₹5.17 | ₹5.42 | ₹5.18 | ₹7.37 | ₹6.65 | ₹7.71 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|
| Sales | 1,081 Cr | 1,244 Cr | 1,630 Cr | Sign in for TTM |
| Operating expenses (approx.) | 927 Cr | 1,058 Cr | 1,387 Cr | Sign in for TTM |
| EBITDA | 154 Cr | 186 Cr | 243 Cr | Sign in for TTM |
| OPM % | 14.3% | 15.0% | 14.9% | Sign in for TTM |
| Other income | 12 Cr | 12 Cr | 7 Cr | Sign in for TTM |
| Interest | 21 Cr | 2 Cr | 17 Cr | Sign in for TTM |
| Depreciation | 16 Cr | 25 Cr | 45 Cr | Sign in for TTM |
| Profit before tax | 130 Cr | 171 Cr | 188 Cr | Sign in for TTM |
| Tax % | 27.2% | 25.0% | 25.1% | Sign in for TTM |
| Net profit | 94 Cr | 128 Cr | 141 Cr | Sign in for TTM |
| EPS (₹) | ₹18.66 | ₹22.41 | ₹24.63 | Sign in for TTM |
| Dividend payout % | 0.0% | 0.0% | 8.1% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Equity capital | 57 Cr | 57 Cr | 57 Cr |
| Reserves | 774 Cr | 902 Cr | 1,034 Cr |
| Borrowings | 245 Cr | 338 Cr | 344 Cr |
| Other liabilities | 245 Cr | 283 Cr | 403 Cr |
| Total liabilities | 1,321 Cr | 1,580 Cr | 1,837 Cr |
| Fixed assets (net) | 340 Cr | 812 Cr | 823 Cr |
| CWIP | 341 Cr | 23 Cr | 16 Cr |
| Investments | 0 Cr | 0 Cr | 41 Cr |
| Loans & advances | 0.44 Cr | 0.68 Cr | 0.44 Cr |
| Inventories | 144 Cr | 208 Cr | 283 Cr |
| Trade receivables | 288 Cr | 332 Cr | 437 Cr |
| Cash & bank | 12 Cr | 16 Cr | 3 Cr |
| Other assets | 195 Cr | 190 Cr | 233 Cr |
| Total assets | 1,321 Cr | 1,580 Cr | 1,837 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Cash from operating activity | 146 Cr | 64 Cr | 117 Cr |
| Cash from investing | -499 Cr | -152 Cr | -107 Cr |
| Cash from financing | 361 Cr | 92 Cr | -22 Cr |
| Net cash flow | 8 Cr | 4 Cr | -12 Cr |
| Free cash flow (OCF − Capex) | -141 Cr | -109 Cr | 48 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| ROCE % | 14.0% | 13.4% | 14.3% |
| ROE % | 0.0% | 0.0% | 0.0% |
| Debtor days | 97 | 97 | 98 |
| Inventory days | 76 | 95 | 103 |
| Days payable | 94 | 92 | 115 |
| Cash conversion cycle | 79 | 100 | 85 |
| Debt / equity | 0.29 | 0.35 | 0.32 |
| Current ratio | 2.18 | 1.97 | 1.87 |
| Net debt / EBITDA | 1.51 | 1.73 | 1.40 |
Compare with peers
Loading peers…